The latest news and events from ECRIN and its partners

EJP RD Joint Transnational Call 2020

20 November 2019

The Preliminary Announcement of the European Joint Programme on Rare Diseases (EJP RD) Joint Transnational Call (JTC) 2020 is online.

The topic is: PRE-CLINICAL RESEARCH TO DEVELOP EFFECTIVE THERAPIES FOR RARE DISEASES.

There will be a two-stage submission procedure for joint applications: pre-proposals and full proposals. The call is scheduled to open on December 13, 2019.

Background

The ERA-Net E-Rare has successfully implemented 10 Joint Transnational Calls for rare disease research projects since 2006. This effort continues in the framework of the European Joint Programme on Rare Diseases (EJP RD), which was established to further help in coordinating the research efforts of European, Associated and non-European countries in the field of rare diseases and to implement the objectives of the International Rare Disease Research Consortium (IRDiRC).

A number of national and regional funding organisations will participate in the EJP RD JTC 2020 and will fund multilateral research projects on rare diseases together with the European Commission (EC) under the EJP-COFUND action. 

Topics

Research proposals must cover at least one of the following areas:

1. Development of novel therapies in a preclinical setting (including small molecules, repurposing drugs, cell and gene advanced therapies) focusing on condition(s) with unmet medical needs

2. Use of disease models suitable for medicinal product’s development according to EMA guidelines

3. Development of predictive and pharmacodynamics (PD) biomarkers (with appropriate analytical methods e.g. OMICS) in a preclinical setting (e.g. in the validated model or in pre-collected human samples) for monitoring the efficiency of the therapy. The model chosen must mimic the human diseases and be transposable so that the biomarker identified in animals can be valid for humans

4. Proof of principle studies fostering an early (pre-clinical) stage of drug development (excluding interventional clinical trials of phase 1-4).

For more information, including consortium makeup and timetables, please view the EJP RD call page

EJP RD has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement number 825575.